AstraZeneca’s Nexium Marketing Targeted In Consumer Suit
This article was originally published in The Tan Sheet
Executive Summary
A lawsuit filed in U.S. Superior Court in Los Angeles alleges AstraZeneca employed "unfair and deceptive" practices in promoting its proton pump inhibitor Nexium (esomeprazole)
You may also be interested in...
AstraZeneca subpoenaed
Pennsylvania U.S. Attorney is seeking documents related to the formulary status of proton pump inhibitors Prilosec and Nexium at a regional health maintenance organization and a national pharmacy benefits manager, AstraZeneca announces in recent third-quarter earnings report. The firm says it "intends to cooperate fully" with the document requests. AstraZeneca's Nexium marketing is the target of a consumer suit filed in U.S. Superior Court last month (1"The Tan Sheet" Oct. 24, 2004, p. 11)...
AstraZeneca subpoenaed
Pennsylvania U.S. Attorney is seeking documents related to the formulary status of proton pump inhibitors Prilosec and Nexium at a regional health maintenance organization and a national pharmacy benefits manager, AstraZeneca announces in recent third-quarter earnings report. The firm says it "intends to cooperate fully" with the document requests. AstraZeneca's Nexium marketing is the target of a consumer suit filed in U.S. Superior Court last month (1"The Tan Sheet" Oct. 24, 2004, p. 11)...
AstraZeneca subpoenaed
Pennsylvania U.S. Attorney is seeking documents related to the formulary status of proton pump inhibitors Prilosec and Nexium at a regional health maintenance organization and a national pharmacy benefits manager, AstraZeneca announces in recent third-quarter earnings report. The firm says it "intends to cooperate fully" with the document requests. AstraZeneca's Nexium marketing is the target of a consumer suit filed in U.S. Superior Court last month (1"The Tan Sheet" Oct. 24, 2004, p. 11)...